Hikma

Hikma Buys Teligent’s Canadian Assets

The UK’s Hikma Pharmaceuticals has agreed to pay $45.75 million for the Canadian business of Teligent, a US generic drugmaker that filed for Chapter 11 bankruptcy protection in October 2021 and initiated a sale of its core assets. The deal is expected to close before the end of the first quarter of 2022.

Pharma In Africa

Hikma Eyes Options for Injectables Business

Hikma Looking to Expand in Africa